Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor by GREEN, Lisa J, MARDER, Philip, ECKHARDT, S. Gail, THORNTON, Donald, RAY, Chad, COOK, Carolyn A, JAKEN, Susan, MUSIB, Luna C, HERBST, Roy S, CARDUCCI, Michael, BRITTEN, Carolyn D, BASCHE, Michele

Get full text

Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Canc... by Dickgreber, Nicolas J, Fink, Thomas H, Latz, Jane E, Hossain, Anwar M, Musib, Luna C, Thomas, Michael

Get full text

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-β Inhibitor, in Healthy Subjects by Welch, Pamela A., Sinha, Vikram P., Cleverly, Ann L., Darstein, Christelle, Flanagan, Shawn D., Musib, Luna C.

Get full text

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients by Specenier, Pol M, Ciuleanu, Tudor, Latz, Jane E, Musib, Luna C, Darstein, Christelle L. S, Vermorken, Jan B

Get full text

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-{szligbeta} Inhibitor, in Healthy Subjects by Welch, Pamela A, Sinha, Vikram P, Cleverly, Ann L, Darstein, Christelle, Flanagan, Shawn D, Musib, Luna C

Get full text

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-{beta} Inhibitor by Green, Lisa J, Marder, Philip, Ray, Chad, Cook, Carolyn A, Jaken, Susan, Musib, Luna C, Herbst, Roy S, Carducci, Michael, Britten, Carolyn D, Basche, Michele, Eckhardt, SGail, Thornton, Donald

Get full text

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally adva... by Shapiro, Geoffrey I., LoRusso, Patricia, Cho, Daniel C., Musib, Luna, Yan, Yibing, Wongchenko, Matthew, Chang, Ilsung, Patel, Premal, Chan, Iris T., Sanabria-Bohorquez, Sandra, Meng, Raymond D., Bendell, Johanna C.

Get full text

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans by Takahashi, Ryan H, Choo, Edna F, Ma, Shuguang, Wong, Susan, Halladay, Jason, Deng, Yuzhong, Rooney, Isabelle, Gates, Mary, Hop, Cornelis E.C.A, Khojasteh, S. Cyrus, Dresser, Mark J, Musib, Luna

Get full text

The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer... by GRAFF, Jeremy R, MCNULTY, Ann M, SAMS, Lillian, HUSS, Karen L, CAMPBELL, Robert M, IVERSEN, Philip W, NEUBAUER, Blake Lee, BROWN, Thomas J, MUSIB, Luna, GEEGANAGE, Sandaruwan, THORNTON, Donald, ROSS HANNA, Kimberly, KONICEK, Bruce W, LYNCH, Rebecca L, BAILEY, Spring N, BANKS, Crystal, CAPEN, Andrew, GOODE, Robin, LEWIS, Jason E

Get full text

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with... by Bendell, Johanna C., LoRusso, Patricia, Cho, Daniel C., Musib, Luna, Yan, Yibing, Chang, Ilsung, Patel, Premal, Chang, Iris T., Meng, Raymond D., Shapiro, Geoffrey I.

Get full text

Safety of an IV formulation of carbamazepine by Conway, Jeannine M, White, James R, Birnbaum, Angela K, Eugene Ramsay, R, Pennell, Page B, Rarick, John O, Musib, Luna, Leppik, Ilo E, Cloyd, James C

Get full text